COVID-19 Disease and Interferon-γ: Has it aProtective Impact on Mortality?

Kamil, Anton Abdulbasah; ALOUDAL, Mohammad Reza; HUSSEİNİ, Abbas Ali

doi:10.14744/etd.2020.40326

COVID-19 Disease and Interferon-γ: Has it aProtective Impact on Mortality?

Abbas Ali HUSSEİNİ, (İstanbul Gelişim Üniversitesi, Yaşam Bilimleri ve Biyomedikal Mühendislik Uygulaması ve Araştırma Merkezi, İstanbul, Türkiye)

Anton Abdulbasah KAMİL, (İstanbul Gelişim Üniversitesi, İdari ve Sosyal Bilimler Fakültesi, İstanbul, Türkiye)

Mohammad Reza ALOUDAL (World Health Organization, National Professional Officer (NPO), Afghanistan)

Erciyes Medical Journal

3 2

Yıl: 2021 Cilt: 43 Sayı: 2 Sayfa Aralığı: 116 - 121 Metin Dili: İngilizce DOI: 10.14744/etd.2020.40326 İndeks Tarihi: 31-01-2022

COVID-19 Disease and Interferon-γ: Has it aProtective Impact on Mortality?

Öz:

The complex coincidence of several immunopathological, socio-cultural, and health infrastructure factors may affect theCOVID-19 related mortality among different populations. The impact of the age on disease progression has been confirmedin several studies. Recently limited ecological and clinical studies have sparked controversy among researchers about theprotective impact of the non-specific effect of routinely used Bacille Calmette-Guerin (BCG), Hepatitis A virus (HAV), andinfluenza (Flu) vaccines or their natural infections against COVID-19. In the present study, variables, including BCG vaccina tion coverage, HAV prevalence, and population age distributions, from 59 countries were analyzed to examine their potentialassociation with COVID-19 infection and related mortality rate. Concerning COVID-19 cases/million population (1MP) andmortality, there are significant differences between countries with and without BCG vaccination programs (p-value <0.001).A significant negative correlation between both BCG coverage and HAV prevalence with COVID-19 related mortality wasalso found (r (59)=-0.4, p-value <0.05), (r (59) =-0.3, p-value <0.01). Based on the results of the present study, previousecological analyses and available epidemiological evidence, along with knowledge of the immune response to BCG, HAV andinfluenza vaccination, as well as COVID-19 infection progression, the current study suggest a hypothesis that IFN-γ inducedimmune response which could be triggered by BCG, HAV, and flu vaccination or natural infections may have a protectiveeffect against COVID-19 related mortality.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Husseini AA, Kamil AA. Estimating COVID-19 Dynamics in Afghanistan. Erciyes Med J 2020; 42(4): 468–73. doi: 10.14744/ etd.2020.80270. [Epub ahead of print].
2. European Centre for Disease Prevention and Control. “Situation updates on COVID-19”. Available from: URL: https://www.ecdc.europa.eu/en. Accessed Jun 15, 2020.
3. Gaythorpe K, Imai N, Cuomo-Dannenburg G, Baguelin M, Bhatia S, Boonyasiri A, et al. Report 8: Symptom progression of COVID-19. Available from: URL: https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-College-COVID19-symptom-progression-11-03-2020.pdf.
4. Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. MedRxiv. 2020 March 28. doi: 10.1101/2020.03.24.20042937. [Epub ahead of print].
5. Gursel M, Gursel I. Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic? Allergy. 2020 April 27. doi: 10.1111/all.14345 [Epub ahead of print].
6. Worldometer. Coronavirus update (live), 2020. Available from: URL: https://www.worldometers.info/coronavirus/?utm_campaign=homeADemocracynow(2020)%20dvegas1? Accessed Jun 15, 2020.
7. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054–62.
8. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020; 146(1): 110–18.
9. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care 2020; 24(1): 108.
10. Center for Disease Control and Prevention. COVID-19 Response Team. Severe Outcomes among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. Morbidity Mortality Weekly Report. Weekly 2020; 69(12): 343–6.
11. Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, et al. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. Clin Microbiol Infect 2020; 26(6): 767–72.
12. Sarialioglu F, Belen Apak FB, Haberal M. Can Hepatitis A Vaccine Provide Protection Against COVID-19?. Exp Clin Transplant 2020; 18(2): 141–3.
13. Horns F, Dekker CL, Quake SR. Memory B Cell Activation, Broad Anti-influenza Antibodies, and Bystander Activation Revealed by Single-Cell Transcriptomics. Cell Rep 2020; 30(3): 905–13.e6.
14. A Database of Global BCG Vaccination Policies and Practices. The BCG World Atlas, second edition. Available from: URL: http://www. bcgatlas.org/.
15. World map of HAV prevalence. Available from: URL: http://www. cdc.gov/travel/yellowbook/2012/ chapter-3- infectious-diseases-related-to-travel/hepatitis-a.htm#362.
16. BCG vaccines: WHO position paper – February 2018. Vaccins BCG: Note de synthèse de l’OMS – Février 2018. [Article in French]. Wkly Epidemiol Rec 2018; 93(8): 73–96.
17. Ozdemir C, Kucuksezer UC, Tamay ZU. Is BCG vaccination affecting the spread and severity of COVID-19?. Allergy 2020; 75(7): 1824–7.
18. Madan M, Pahuja S, Mohan A, Pandey RM, Madan K, Hadda V, et al. TB infection and BCG vaccination: are we protected from COVID-19? Public Health 2020; 185: 91–2.
19. Thwaites GE, van Toorn R, Schoeman J. Tuberculous meningitis: more questions, still too few answers. Lancet Neurol 2013; 12(10): 999–1010.
20. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006; 367(9517): 1173–80.
21. Moorlag SJCFM, Arts RJW, van Crevel R, Netea MG. Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect 2019; 25(12): 1473–8.
22. Alhunaidi O, Zlotta AR. The use of intravesical BCG in urothelial carcinoma of the bladder. Ecancermedicalscience 2019; 13: 905.
23. O’Neill LAJ, Netea MG. BCG-induced trained immunity: can it offer protection against COVID-19? Nat Rev Immunol 2020; 20(6): 335–7.
24. Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, et al. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. N Engl J Med 2018; 379(2): 138–49.
25. Curtis N, Sparrow A, Ghebreyesus TA, Netea MG. Considering BCG vaccination to reduce the impact of COVID-19. Lancet 2020; 395(10236): 1545–6.
26. Kelleni MT. Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management. Pharmacol Res 2020; 157: 104874.
27. Sarialioğlu F, Belen FB, Hayran KM. Hepatitis A susceptibility parallels high COVID-19 mortality. Turk J Med Sci. 2020 Jul 28. doi: 10.3906/sag-2007-133. [Epub ahead of print].
28. Salem ML, El-Hennawy D. The possible beneficial adjuvant effect of influenza vaccine to minimize the severity of COVID-19. Med Hypotheses. 2020 Apr 22. doi: 10.1016/j.mehy.2020.109752 [Epub ahead of print].
29. Zheng J, Perlman S. Immune responses in influenza A virus and human coronavirus infections: an ongoing battle between the virus and host. Curr Opin Virol 2018; 28: 43–52.
30. Zeng Q, Langereis MA, van Vliet AL, Huizinga EG, de Groot RJ. Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution. Proc Natl Acad Sci U S A 2008; 105(26): 9065–9.
31. Abdella R, Aggarwal M, Okura T, Lamb RA, He Y. Structure of a paramyxovirus polymerase complex reveals a unique methyltransferase-CTD conformation. Proc Natl Acad Sci U S A 2020; 117(9): 4931–41.
32. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. J Infect 2020; 80(6): 607–13.
33. Lagunas-Rangel FA, Chávez-Valencia V. High IL-6/IFN-γ ratio could be associated with severe disease in COVID-19 patients J Med Virol. 2020 Apr 16. doi: 10.1002/jmv.25900. [Epub ahead of print].
34. Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2020 June 27. doi:10.1002/jmv.26232. [Epub ahead of print]
35. Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest 2020; 130(5): 2202–5.
36. Liu J, Li S, Liu J, Liang B, Wang X, Wang H et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 2020; 55: 102763.
37. Sun D, Li H, Lu XX, Xiao H, Ren J, Zhang FR, et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center’s observational study. World J Pediatr 2020; 16(3): 251–9.
38. Li Q, Li J, Tian J, Zhu B, Zhang Y, Yang K, et al. IL-17 and IFN-γ production in peripheral blood following BCG vaccination and Mycobacterium tuberculosis infection in human. Eur Rev Med Pharmacol Sci 2012; 16(14): 2029–36.
39. Schepers K, Dirix V, Mouchet F, Verscheure V, Lecher S, Locht C, et al. Early cellular immune response to a new candidate mycobacterial vaccine antigen in childhood tuberculosis. Vaccine 2015; 33(8): 1077–83.
40. Abebe F. Is interferon-gamma the right marker for bacille CalmetteGuérin-induced immune protection? The missing link in our understanding of tuberculosis immunology. Clin Exp Immunol 2012; 169(3): 213–9.
41. Garner-Spitzer E, Kundi M, Rendi-Wagner P, Winkler B, Wiedermann G, Holzmann H, et al. Correlation between humoral and cellular immune responses and the expression of the hepatitis A receptor HAVcr-1 on T cells after hepatitis A re-vaccination in high and low-responder vaccinees. Vaccine 2009; 27(2): 197–204.
42. Hayney MS, Buck JM, Muller D. Production of interferon-gamma and interleukin-10 after inactivated hepatitis A immunization. Pharmacotherapy 2003; 23(4): 431–5.
43. Kak G, Raza M, Tiwari BK. Interferon-gamma (IFN-γ): Exploring its implications in infectious diseases. Biomol Concepts 2018; 9(1): 64–79.
44. Kronstad LM, Seiler C, Vergara R, Holmes SP, Blish CA. Differential Induction of IFN-α and Modulation of CD112 and CD54 Expression Govern the Magnitude of NK Cell IFN-γ Response to Influenza A Viruses. J Immunol 2018; 201(7): 2117–31.
45. Dutta A, Miaw SC, Yu JS, Chen TC, Lin CY, Lin YC, et al. Altered T-bet dominance in IFN-γ-decoupled CD4+ T cells with attenuated cytokine storm and preserved memory in influenza. J Immunol 2013; 190(8): 4205–14.

APA	HUSSEİNİ A, Kamil A, ALOUDAL M (2021). COVID-19 Disease and Interferon-γ: Has it aProtective Impact on Mortality?. , 116 - 121. 10.14744/etd.2020.40326
Chicago	HUSSEİNİ Abbas Ali,Kamil Anton Abdulbasah,ALOUDAL Mohammad Reza COVID-19 Disease and Interferon-γ: Has it aProtective Impact on Mortality?. (2021): 116 - 121. 10.14744/etd.2020.40326
MLA	HUSSEİNİ Abbas Ali,Kamil Anton Abdulbasah,ALOUDAL Mohammad Reza COVID-19 Disease and Interferon-γ: Has it aProtective Impact on Mortality?. , 2021, ss.116 - 121. 10.14744/etd.2020.40326
AMA	HUSSEİNİ A,Kamil A,ALOUDAL M COVID-19 Disease and Interferon-γ: Has it aProtective Impact on Mortality?. . 2021; 116 - 121. 10.14744/etd.2020.40326
Vancouver	HUSSEİNİ A,Kamil A,ALOUDAL M COVID-19 Disease and Interferon-γ: Has it aProtective Impact on Mortality?. . 2021; 116 - 121. 10.14744/etd.2020.40326
IEEE	HUSSEİNİ A,Kamil A,ALOUDAL M "COVID-19 Disease and Interferon-γ: Has it aProtective Impact on Mortality?." , ss.116 - 121, 2021. 10.14744/etd.2020.40326
ISNAD	HUSSEİNİ, Abbas Ali vd. "COVID-19 Disease and Interferon-γ: Has it aProtective Impact on Mortality?". (2021), 116-121. https://doi.org/10.14744/etd.2020.40326

APA	HUSSEİNİ A, Kamil A, ALOUDAL M (2021). COVID-19 Disease and Interferon-γ: Has it aProtective Impact on Mortality?. Erciyes Medical Journal, 43(2), 116 - 121. 10.14744/etd.2020.40326
Chicago	HUSSEİNİ Abbas Ali,Kamil Anton Abdulbasah,ALOUDAL Mohammad Reza COVID-19 Disease and Interferon-γ: Has it aProtective Impact on Mortality?. Erciyes Medical Journal 43, no.2 (2021): 116 - 121. 10.14744/etd.2020.40326
MLA	HUSSEİNİ Abbas Ali,Kamil Anton Abdulbasah,ALOUDAL Mohammad Reza COVID-19 Disease and Interferon-γ: Has it aProtective Impact on Mortality?. Erciyes Medical Journal, vol.43, no.2, 2021, ss.116 - 121. 10.14744/etd.2020.40326
AMA	HUSSEİNİ A,Kamil A,ALOUDAL M COVID-19 Disease and Interferon-γ: Has it aProtective Impact on Mortality?. Erciyes Medical Journal. 2021; 43(2): 116 - 121. 10.14744/etd.2020.40326
Vancouver	HUSSEİNİ A,Kamil A,ALOUDAL M COVID-19 Disease and Interferon-γ: Has it aProtective Impact on Mortality?. Erciyes Medical Journal. 2021; 43(2): 116 - 121. 10.14744/etd.2020.40326
IEEE	HUSSEİNİ A,Kamil A,ALOUDAL M "COVID-19 Disease and Interferon-γ: Has it aProtective Impact on Mortality?." Erciyes Medical Journal, 43, ss.116 - 121, 2021. 10.14744/etd.2020.40326
ISNAD	HUSSEİNİ, Abbas Ali vd. "COVID-19 Disease and Interferon-γ: Has it aProtective Impact on Mortality?". Erciyes Medical Journal 43/2 (2021), 116-121. https://doi.org/10.14744/etd.2020.40326